



ALTERNATIVE TO PTO/SB/08A/B  
(Based on PTO 01-08 version)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/687,951
				Filing Date	October 13, 2000
				First Named Inventor	Jeffrey CLELAND
				Art Unit	1656
				Examiner Name	C. Kam
Sheet	1	of	2	Attorney Docket Number	146392002300

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-2007/0098736-A1	05-03-2007	Cleland et al.	
	2.	US-3,523,906	08-11-1970	Vranchen et al.	
	3.	US-3,691,090	09-12-1972	Kitajima et al.	
	4.	US-3,737,337	06-05-1973	Schnoring et al.	
	5.	US-4,389,330	06-21-1983	Tice et al.	
	6.	US-5,019,400	05-28-1991	Gombotz et al.	
	7.	US-5,204,382	04-20-1993	Wallace et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	8.	WO-95/16464-A1	06-22-1995	Johns Hopkins University School of Medicine		
	9.	WO-95/29664-A1	11-09-1995	Alkermes Controlled Therapeutics, Inc.		
	10.	WO-98/51348-A2, A3	11-19-1998	Amgen, Inc.		
	11.	WO-01/28591-A2, A3	04-26-2001	Genentech, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	12.	Cowsar, D.R. et al. (1985). "Poly(lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," Chapter 8 in <i>Methods in Enzymology</i> , 112:101-116.	
	13.	Holland, S.J. et al. (1986). "Polymers for Biodegradable Medical Devices. 1. The Potential of Polyesters as Controlled Macromolecular Release Systems," <i>J. Controlled Release</i> 4:155-180.	
	14.	Lewis, D.H. et al. (1990). "Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers," Chapter 1 in <i>Biodegradable Polymers as Drug Delivery Systems</i> , Marcel Dekker, Inc.:New York, NY, pp. 1-41.	
	15.	Maulding, H.V. (1987). "Prolonged Delivery of Peptides by Microcapsules," <i>J. Controlled Release</i> 6:167-176.	
	16.	Non-Final Office Action mailed November 9, 2007, for U.S. Patent Application Serial No. 11/614,462, 9 pages.	
	17.	Office Action mailed August 13, 2007, for Canadian Patent Application No. 2,387,058, three pages.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/687,951
				Filing Date	October 13, 2000
				First Named Inventor	Jeffrey CLELAND
				Art Unit	1656
				Examiner Name	C. Kam
Sheet	2	of	2	Attorney Docket Number	146392002300

	18.	Ogawa Y. et al. (March 1988). "A New Technique to Efficiently Entrap Leuprolide Acetate into Microcapsules of Polylactic Acid of Copoly(Lactic/Glycolic) Acid," <i>Chem. Pharm. Bull.</i> 36(3):1095-1103.	
	19.	Ogawa, Y. et al. (July 1988). " <i>In Vivo</i> Release Profiles of Peuprolide Acetate from Microcapsules Prepared with Polylactic Acids or Copoly(Lactic/Glycolic) Acids and <i>in Vivo</i> Degradation of These Polymers," <i>Chem. Pharm. Bull.</i> 36(7):2576-2581.	
	20.	Restriction Requirement mailed June 25, 2007, for U.S. Patent Application Serial No. 11/614,462, 5 pages.	
	21.	Sanders, L.M. et al. (April 1986). "Prolonged Controlled-Release of Nafarelin, a Luteinizing Hormone-Releasing Hormone Analogue, From Biodegradable Polymeric Implants: Influence of Composition and Molecular Weight of Polymer," <i>J. Pharm. Sci.</i> 75(4):356-360.	
	22.	Smith, K.L. et al. (January-April 1990). "Bioerodible Polymers for Delivery of Macromolecules," <i>Advanced Drug Delivery Reviews</i> 4(3):343-357.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.